AMGEN Inc
Amgen is a global leader in biotechnology, developing innovative treatments for serious diseases in various areas such as oncology, cardiology, and neurology.
Price history of AMGEN Inc
Price history of AMGEN Inc
Performance & Momentum
Amgen Set to Slash Amjevita via TrumpRx
Amgen is expected to join the TrumpRx program alongside GSK to offer steep discounts on prescription drugs. According to reports, Amgen would notably offer an 80% cut on Amjevita, its treatment for rheumatoid arthritis, psoriasis and ulcerative colitis. The move could improve patient access and strengthen ties with regulators, but it may also weigh on the group’s margins and revenue in the near term. For AMGN shares, the market reaction could be mixed to negative if investors focus mainly on the impact on profitability.
Strategic Analysis
AMGEN Inc • 2026
Amgen is a well-established U.S. biopharmaceutical company, combining a portfolio of marketed treatments with a strong focus on oncology, inflammation, and rare diseases. Its positioning is based on its ability to monetize medical research while relying on high-value therapeutic franchises, in a sector where innovation and regulatory barriers protect the strongest players.
- Presence in attractive and differentiated medical segments, with long-term structural demand
- Large-cap profile providing an established commercial base and greater operational visibility than many biotechs
- Solid stock market track record across multiple horizons, reflecting the market’s lasting appreciation for the quality of the story
- Ongoing dependence on successful pipeline renewal to support future growth
- Inherent exposure to regulatory, clinical, and competitive risks specific to biopharma
Momentum is favorable and suggests the market has become more receptive to the stock again, with positive dynamics that appear durable rather than just a tactical rebound. The trend remains constructive for a long-term investor, even if the stock retains the sector’s usual sensitivity to clinical announcements, pipeline execution, and competitive pressure.
Similar stocks to AMGEN Inc
Recent News
AMGEN Inc
Amgen Raises $4B in Long-Term Bonds to Fund Growth
3 months agoOn February 17, 2026, Amgen raised approximately $3.96 billion through a multi-tranche bond issuance with maturities extending to 2056. This move reflects the company’s strategy to optimize its capital structure to support its long-term investment plans. Additionally, Amgen shares benefit from a bullish sentiment, boosted by an attractive valuation with a forward P/E ratio around 13.74, appealing to value-seeking investors in the biotech sector. This positive momentum could support AMGN stock on the NASDAQ in the coming months.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
